Find Funding Opportunities

To have a broader impact on the clinical practice of undiagnosed diseases in the US, the NIH envisions the Undiagnosed Diseases Network, a Common Fund program, evolving into a larger, self-sustained network that, with public and private partners, can provide expert diagnostic services for diverse populations across the nation and foster scientific discovery. This Notice informs the research community that NIH intends to publish a Funding Opportunity Announcement (FOA) that solicits applications for the development of a Data Management and Coordinating Center (DMCC). The DMCC is intended to provide coordination infrastructure, data management, and clinical research support for a new network of clinical sites. Sites across the US that provide expert diagnostic services for patients with undiagnosed diseases will be solicited to join a collaborative effort that is coordinated by the DMCC to promote diagnosis and the discovery of new disease-associated genes and genomic variants, immunologic and metabolic abnormalities, as well as environmental insults that are causative in previously undiagnosed patients. In this new model, the network will consist of the DMCC, highly qualified and collaborative clinical sites [designated Diagnostic Centers of Excellence (DCoEs)], the Undiagnosed Diseases Program (UDP), participants with undiagnosed diseases and patient advocacy groups, the NIH and other stakeholders including external funding or resource providers. A related Notice (NOT-NS-22-072) describes the application process and requirements for clinical sites to join the future network.

To have a broader impact on the clinical practice of undiagnosed diseases in the US, the NIH envisions the Undiagnosed Diseases Network, a Common Fund program, evolving into a larger, self-sustained network that, with public and private partners, can provide expert diagnostic services for diverse populations across the nation and foster scientific discovery. To assist in the transition towards sustainability, the NIH intends to fund a Data Management and Coordinating Center (DMCC) to provide coordination infrastructure, data management, and clinical research support to clinical sites with expertise in diagnosing challenging and difficult-to-diagnose diseases (see related Notice). A Funding Opportunity Announcement (FOA) to solicit applications for the DMCC is expected to be published in spring of 2022. This Notice informs the research community that NIH intends to publish a Program Announcement that solicits proposals from highly qualified clinical sites in the US to join the new network through an X01 Resource Access Program award.

The purpose of this notice is to direct visitors who land on the terminated FOA PAR-19-164 to the current FOA PAR-21-168.

The purpose of this notice is to inform applicants of a correction to PAR-21-237 "NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)".

The purpose of this notice is to inform applicants of NINDS' participation in RFA-MD-22-004 "Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional)" effective immediately.

The purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery of strong candidate biomarkers or biomarker signatures for pain that can be used to facilitate the testing of non-opioid pain therapeutics in Phase II clinical trials.The biomarkers or biomarker signature will be developed through clinical research specifically focused on the identification of pain biomarkers or biosignatures that predict and/or monitor response to pain therapeutics. The resulting biomarkers or biomarker signatures may be focused on a single pain condition or on several pain conditions with common underlying pathophysiology. Applications to identify biomarkers or biomarker signatures that predict or monitor a therapeutic response across several related pain conditions should feature Multiple Principal Investigator (MPI)-led teams that represent each of the related pain conditions and associated clinical networks. The MPI-led teams are expected to decide upon a single set of measures or biomarker modalities (i.e., combination of omics, QST, actigraphy, EEG, digital measures, etc.) as components of the biosignature for all pain conditions represented in the application. Applications should feature centralized resource groups that will coordinate clinical trials and standardize all sample or data collection methods, technology development, statistical analysis and algorithm development across the pain conditions under investigation. Applications seeking to develop biomarkers or biomarker signatures that will be used to predict and/or monitor a therapeutic response for a single pain condition must also feature MPI-led teams that represent the cross functional expertise necessary for biomarker and/or signature development, along with the same types of centralized resource groups that coordinate clinical trials and standardize sample or data collection methods, technology development and statistical analysis.

The purpose of this time-sensitive Request for Information (RFI) is to solicit public input to the NINDS regarding the challenges and opportunities in fundamental neuroscience research to best understand the normal development, structure, and function of nervous systems.

The purpose of this time-sensitive Request for Information (RFI) is to solicit public input to the NINDS regarding the challenges and opportunities in fundamental neuroscience research to best understand the normal development, structure, and function of nervous systems.

The purpose of this notice is to correct the Award Project Period Information for Funding Opportunity Announcement (FOA) PAS-19-316 "Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional). According to statutory guidelines, award periods normally may not exceed 2 years for Phase I and 3 years for Phase II. As such, NIA has changed the award period for Phase I from 1 year to 2 years and the award period for Phase II from 2 years to 3 years.

The purpose of this notice is to correct the Award Project Period Information for Funding Opportunity Announcement (FOA) PAS-19-317, "Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional). Specifically, according to statutory guidelines, award periods normally may not exceed 2 years for Phase I and 3 years for Phase II. As such, NIA has changed the award period for Phase I from 1 year to 2 years and the award period for Phase II from 2 years to 3 years.